Sermorelin vs Tirzepatide
Side-by-side comparison of key properties, dosing, and research.
Growth Hormone PeptidesAnti-Aging & Longevity
SermorelinGLP-1 / Weight Loss Agonists
Tirzepatide- Summary
- Sermorelin is a bioidentical synthetic peptide comprising the first 29 amino acids of naturally occurring GHRH. It is FDA-approved for diagnostic use and widely prescribed off-label for anti-aging, stimulating growth hormone production in a natural pulsatile pattern that mimics the body's own rhythm.
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
- Half-Life
- 10–20 minutes
- ~5 days
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 200–500 mcg
- 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
- Frequency
- 5–7 days per week
- Once weekly, subcutaneous
- Key Benefits
- Increases energy and vitality
- Improves body composition (more muscle, less fat)
- Enhances skin thickness and elasticity
- Strengthens immune system
- Improves sleep quality and REM sleep
- Supports bone density
- Enhances mental clarity and focus
- Safer than exogenous HGH — respects natural feedback loops
- FDA-approved for GH diagnostic use
- Average 21% body weight reduction at highest dose (SURMOUNT-1)
- Superior to semaglutide in head-to-head SURPASS trials
- Dual GIP/GLP-1 mechanism for enhanced metabolic control
- Significant reduction in HbA1c for type 2 diabetes
- Improved cardiovascular risk markers
- Reduces visceral fat preferentially
- FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
- Weekly dosing
- Side Effects
- Injection site irritation
- Flushing
- Headache
- Dizziness
- +2 more
- Nausea (most common during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal pain
- +3 more
- Stacks With
- —
- —